Company Description
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system.
This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency.
The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare under the BioReference brand; and 4Kscore test.
OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2006 |
| IPO Date | Nov 2, 1995 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,275 |
| CEO | Phillip Frost |
Contact Details
Address: 4400 Biscayne Boulevard Miami, Florida 33137 United States | |
| Phone | 305 575 4100 |
| Website | opko.com |
Stock Details
| Ticker Symbol | OPK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000944809 |
| CUSIP Number | 68375N103 |
| ISIN Number | US68375N1037 |
| Employer ID | 75-2402409 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Phillip Frost M.D., Ph.D. | Chairman and Chief Executive Officer |
| Dr. Jane H. Hsiao M.B.A., Ph.D. | Vice Chairman and Chief Technical Officer |
| Dr. Elias Adam Zerhouni M.D. | President and Vice Chairman |
| Adam E. Logal | Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer |
| Steven D. Rubin Esq., J.D. | Executive Vice President of Administration and Director |
| Dr. Gary J. Nabel M.D., Ph.D. | Chief Information Officer and Director |
| Dr. Arie Gutman Ph.D. | President of API |
| Dr. Akhtar Ashfaq FACP, FASN, M.D. | Senior Vice President of Clinical Research and Development and Medical Affairs - Opko Renal |
| Giovanni Abbadessa M.D., Ph.D. | Chief Medical Officer of ModeX |
| Dr. John R. Mascola M.D. | Chief Scientific Officer of ModeX |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Oct 29, 2025 | 10-Q | Quarterly Report |
| Oct 29, 2025 | 8-K | Current Report |
| Oct 1, 2025 | SCHEDULE 13D/A | Filing |
| Sep 15, 2025 | 8-K | Current Report |
| Jul 31, 2025 | 10-Q | Quarterly Report |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 9, 2025 | SCHEDULE 13G/A | Filing |
| May 29, 2025 | 8-K | Current Report |